Use of the opposite cell differentiation program (OCDP) for the treatment of degenerated organs in the pathological state

• US 9,157,065 B2
• Filed: 04/18/2008
• Issued: 10/13/2015
• Est. Priority Date: 09/18/2007
• Status: Active Grant

• Current Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
• Original Assignee: Universitã¤T Leipzig
• Inventors: Buniatian, Gayane, Gebhardt, Rolf, Gleiter, Christoph, Danielyan, Lusine, Proksch, Barbara
• Primary Examiner(s): Mondesi, Robert
• Assistant Examiner(s): Visone, Thomas J
• Application Number:
  US12/678,446
• Publication Number:
  US 20100278786A1
• Time in Patent Office: 2,734 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2502/14 hepatocytes
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Abstract

The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.

Claims

1. A pharmaceutical agent, comprising phenotypically differentiated and activated glial fibrillary acidic protein (GFAP)-positive hepatic stellate cells and adult mesangial cells of the kidney having differentiation features in terms of dynamics of GFAP-expression opposite to astrocytes, and being suitable for use in the treatment of a neurodegenerative disease and/or for the treatment of a disease which is characterized by a loss of neurons and/or for the treatment of a disease which is characterized by a loss of neuronal functionality and/or for the treatment of a neurological disease which is characterized by changes in brain specific homeostasis.

2. The pharmaceutical agent according to claim 1, wherein the disease is Alzheimer'"'"'s disease, multiple sclerosis, and/or Parkinson'"'"'s disease.